Uslu, Ugur http://orcid.org/0000-0001-8109-7892
Sun, Lijun
Castelli, Sofia http://orcid.org/0000-0001-6185-2838
Finck, Amanda V. http://orcid.org/0000-0001-9595-8470
Assenmacher, Charles-Antoine
Young, Regina M.
Chen, Zhijian J. http://orcid.org/0000-0002-8475-8251
June, Carl H. http://orcid.org/0000-0003-0241-3557
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA214278)
Article History
Received: 10 October 2023
Accepted: 10 April 2024
First Online: 10 May 2024
Competing interests
: R.M.Y. and C.H.J. are inventors on patents and/or patent applications licensed to Novartis Institutes of Biomedical Research and receive license revenue from such licenses. C.H.J. is an inventor on patents and/or patent applications licensed to Kite Pharma, Capstan Therapeutics. Dispatch Therapeutics and BlueWhale Bio. C.H.J. is a member of the scientific advisory boards of AC Immune, BluesphereBio, BlueWhale Bio, Cabaletta, Carisma, Cartography, Cellares, Celldex, Decheng, Poseida, Replay Bio, Verismo, and WIRB-Copernicus. L.S. and Z.J.C. are inventors of US patents covering STING agonists including IMSA101 (10,336,786 and 10,519,188). L.S. is an employee of ImmuneSensor Therapeutics. Z.J.C. is a scientific collaborator with Pfizer and ImmuneSensor Therapeutics, and a scientific advisor for Brii Biosciences. No competing interests were declared by the other authors.